# LQT Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lqt-therapeutics

- Industry: Biotechnology
- Headquarters: Laval, Canada
- Website: www.lqttrx.com
- Total disclosed funding: $19M
- Latest round: Series A (Aug 10, 2021)
- Investors on record: 5

## About

LQT Therapeutics, Inc. is a Canadian biotechnology company focused on developing innovative therapies for serious cardiac conditions, particularly Long QT Syndrome and atrial fibrillation, through advanced precision medicine solutions.Founded in 2014 and headquartered in Laval, Canada, LQT Therapeutics, Inc. specializes in precision medicine targeting serious cardiac conditions. The company has completed 2 deals, with its most recent funding round occurring on August 10, 2021, when it raised USD 19.00 mn in a Series A round led by Amplitude, with participation from Alexandria Venture Investments, Amzak Capital Management, Lumira Ventures, and returning investor Fonds de solidarité FTQ Investissements. The firm was co-founded by Philip Sager.LQT Therapeutics develops precision medicine solutions aimed at addressing serious cardiac conditions, notably Long QT Syndrome (LQTS), atrial fibrillation, and heart failure. The company's primary focus is on selective inhibitors of Serum Glucocorticoid Inducible Kinase (SGK1) designed to enhance cardiac electrical activity and contractility. The firm actively engages in clinical research, validating the efficacy and safety of its products in clinical studies, serving healthcare providers and research institutions primarily in North America, with plans for global outreach.LQT Therapeutics generates revenue through partnerships and collaborations with healthcare institutions and research organizations. The company engages in B2B transactions, providing its SGK1 inhibitors to clinical trial participants as part of ongoing studies. The revenue model includes fees for research and development services, along with potential licensing agreements from successful product outcomes. The revenue is influenced by clinical milestones, partnerships, and the commercialization of its products.Following its recent Series A funding of USD 19.00 mn in August 2021, LQT Therapeutics plans to expand its portfolio of SGK1 inhibitors through phase 1 human clinical studies. The company aims to develop new products targeting serious cardiac conditions, with specific timelines for these developments not disclosed. LQT Therapeutics is also looking to expand its market reach beyond North America into other global markets affected by these conditions, relying on the recent funding to support these initiatives.

## Funding rounds

- Series A, Aug 10, 2021, $19M — Alexandria Venture Investments, Fonds de solidarité FTQ Investissements, Amplitude, Amzak Capital Management, Lumira Ventures

## Investors

- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- Fonds de solidarité FTQ Investissements — Series A
- Amplitude (https://capitalatlas.ai/funds/amplitude) — Series A
- Amzak Capital Management (https://capitalatlas.ai/funds/amzak-capital-management) — Series A
- Lumira Ventures (https://capitalatlas.ai/funds/lumira-ventures) — Series A